Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT03866174
PHASE2

A Study of Psilocybin for Major Depressive Disorder (MDD)

Sponsor: Usona Institute

View on ClinicalTrials.gov

Summary

One hundred participants, ages 21 to 65, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for major depressive disorder (MDD) will be stratified by study site and randomized with a 1-to-1 allocation under double-blind conditions to receive a single 25 mg oral dose of psilocybin or a single 100 mg oral dose of niacin. Niacin will serve as an active placebo. The purpose of this study is to evaluate the potential efficacy of a single 25 mg oral dose of psilocybin for MDD compared to the active placebo in otherwise medically-healthy participants, assessed as the difference between groups in changes in depressive symptoms from Baseline to Day 43 post-dose.

Official title: A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)

Key Details

Gender

All

Age Range

21 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

347

Start Date

2020-01-23

Completion Date

2022-06-28

Last Updated

2026-04-22

Healthy Volunteers

No

Interventions

DRUG

Psilocybin

The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.

DRUG

Niacin

The active placebo is encapsulated using a HPMC capsule and contains 100 mg of pharmaceutical grade niacin.

OTHER

Set and Setting (SaS) Protocol

The SaS Protocol prescribes 6-8 hours of preparatory meetings with two facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two facilitators, and 4 hours of post-dose integration sessions with facilitators. During the dosing session participants are encouraged to wear eyeshades and listen to a curated playlist on headphones.

Locations (11)

University of California, San Francisco

San Francisco, California, United States

Pacific Neuroscience Institute

Santa Monica, California, United States

Yale University

New Haven, Connecticut, United States

Segal Trials

Lauderhill, Florida, United States

Emory University

Atlanta, Georgia, United States

Great Lakes Clinical Trials

Chicago, Illinois, United States

Johns Hopkins University

Baltimore, Maryland, United States

Hassman Research Institute

Berlin, New Jersey, United States

New York University School of Medicine

New York, New York, United States

Cedar Clinical Research

Draper, Utah, United States

University of Wisconsin - Madison

Madison, Wisconsin, United States